Mesenchymal stem cells (MSCs) have been demonstrated to have promising therapeutic benefits for a variety of neurological diseases; however, the underlying mechanisms are poorly understood. Here, we showed that intravitreal infusion of MSCs promoted retinal ganglion cell (RGC) survival in a mouse model of acute glaucoma, with significant inhibition of microglial activation, production of TNF-α, IL-1β, and reactive oxygen species, as well as caspase-8 and caspase-3 activation. In vitro, MSCs inhibited both caspase-8-mediated RGC apoptosis and microglial activation, partly via the action of stanniocalcin 1 (STC1). Furthermore, we found that microRNA-21a-5p (miR-21) and its target, PDCD4, were essential for STC1 production and the neuroprotective property of MSCs in vitro and in vivo. Importantly, miR-21 overexpression or PDCD4 knockdown augmented MSC-mediated neuroprotective effects on acute glaucoma. These data highlight a previously unrecognized neuroprotective mechanism by which the miR-21/ PDCD4 axis induces MSCs to secrete STC1 and other factors that exert neuroprotective effects. Therefore, modulating the miR-21/PDCD4 axis might be a promising strategy for clinical treatment of acute glaucoma and other neurological diseases.
Introduction
Mesenchymal stem cells (MSCs) possess a striking variety of biological functions, from tissue repair and regeneration to immunomodulatory and anti-inflammatory activities (Le and Mougiakakos, 2012; Ma et al., 2014; Wang et al., 2014) . Thus, numerous animal and clinical trials have been conducted to evaluate their use in the treatment of a wide range of diseases (Le and Mougiakakos, 2012; Ma et al., 2014; Wang et al., 2014) .
MSCs have recently received considerable attention for their promising potential in the treatment of neurological diseases, with accumulating evidence demonstrating their neuroprotective effects. In fact, MSC-based therapy has been successfully applied to treat human neurological diseases including spinal cord injury, multiple sclerosis, and retinitis pigmentosa (Venkataramana et al., 2010; Connick et al., 2012; Honmou et al., 2012; Lee et al., 2012) . The neuroprotective property of MSCs is associated with their multipotent differentiating ability, trophic/anti-apoptotic functions, and immunomodulatory/anti-inflammatory effects. In addition, various soluble factors, such as transforming growth factor-β (TGF-β), brain-derived neurotrophic factor (BDNF), stanniocalcin 1 (STC1), platelet-derived growth factor (PDGF), nerve growth factor (NGF), and insulin-like growth factor (IGF), secreted by MSCs are involved in the MSC-mediated neuroprotection. However, the detailed mechanisms are not fully understood.
MicroRNAs (miRNAs) are small (∼22-nucleotide-long) noncoding RNAs that negatively regulate the expression of target genes at the posttranscriptional level. Accumulating evidence shows that miRNAs are actively involved in diverse biological processes, including those related to development, carcinogenesis, and autoimmunity. Recently, the roles of miRNAs in stem cell biology have received increasing attention (Greve et al., 2013; Bu et al., 2016) . Recent studies have suggested that miRNAs play significant roles in stem cell fate determination and other biological functions (Hsieh et al., 2013; Trohatou et al., 2014; Guan et al., 2015; Wei et al., 2015; Okada et al., 2016) . In this study, we investigated the role of miRNA-21a-5p (miR-21) and its target PDCD4 in MSC-mediated neuroprotection using a mouse model of acute glaucoma.
Results

Neuroprotective effects of intravitreal MSC infusion on intraocular pressure-induced retinal damage
We first explored the neuroprotective roles of MSCs in a mouse model of acute glaucoma with intraocular pressure (IOP)-induced retinal damage. In I/R group, retinal damage occurred rapidly in mice upon acute elevation of IOP, as evidenced by retinal edema, vacuolar degeneration, and condensation of nuclear chromatin. Hematoxylin and eosin (H&E) staining showed that the retinal inner plexiform layer (IPL) thickness was significantly decreased on Day 7 after reperfusion ( Figure 1A and B). Fluorogold (FG) analysis demonstrated that the number of retinal ganglion cells (RGCs) was also noticeably decreased on Day 7 after reperfusion ( Figure 1C and D) . In MSC treatment group, MSCs (5 × 10 4 /2 μl) were injected into the vitreous cavity of the right eye of each mouse before acute elevation of IOP. Intravitreal MSC injection significantly attenuated the severity of retinal damage and the amount of RGC death ( Figure 1A-D) . MSCs labeled with celltracker CM-DiI dye were present primarily in the vitreous cavity, and only few cells integrated into the ganglion cell layer (GCL) on Day 7 after reperfusion ( Figure 1E ), indicating that the multipotent differentiation property of MSCs may not be responsible for the neuroprotective effects.
Thus, we next examined whether the anti-apoptotic and/or anti-inflammatory functions of MSCs are involved in the neuroprotection in acute glaucoma. Caspase-8 is regarded as an initiator caspase; its activation leads to the activation of caspase-3 in RGC apoptosis associated with glaucoma (Almasieh et al., 2012) . We found that treatment with MSCs significantly inhibited the activation of caspase-8 and caspase-3 in ischemic retinas ( Figure 1F-I ). In addition, the production of nitrotyrosine, which is a protein derivative of reactive oxygen species (ROS), TNF-α, and IL-1β was significantly increased in ischemic retinas, which was significantly decreased by MSC treatment ( Figure 1J-L) . These findings suggest that anti-apoptotic and/or anti-inflammatory effects are involved in MSC-mediated neuroprotection against IOP-induced retinal damage.
MSCs protect RGCs against oxygen-glucose deprivation and reperfusion-induced apoptosis in vitro
To examine direct anti-apoptotic effect of MSCs on RGCs, primary RGCs were co-cultured with MSCs for 24 h in a transwell system (Costar) to mimic the circumstance in vivo that RGCs have minimal contact with the injected MSCs. The primary RGCs were subject to oxygen-glucose deprivation and reperfusion (OGD/R) for 24 h and showed significantly decreased cell viability, as measured by MTT assay. Co-culturing with MSCs significantly increased cell viability in a dose-dependent manner, with the maximum effect observed at a 2:1 (RGC:MSC) ratio (Figure 2A ). Flow cytometry revealed that the number of apoptotic (PI+/Annexin+) RGCs was increased after OGD/R, which was significantly decreased by co-culturing of primary RGCs with MSCs at a 2:1 ratio ( Figure 2B and C). In addition, the activities of caspase-8 and caspase-3 were increased in RGCs after OGD/R, which was also significantly reduced by co-culturing with MSCs ( Figure 2D-G Figure S2) . The Agilent array composed of 1981 mouse miRNAs was used to evaluate the role of miRNAs in MSCmediated neuroprotection. As shown in Figure 3A , 58 out of 1981 miRNAs were differentially regulated, 31 upregulated and 27 downregulated, in MSCs after OGD/R (fold change >2, P < 0.05). Among these differentially expressed miRNAs, miR-21 was upregulated after OGD/R, and its expression was further enhanced in MSCs co-cultured with RGCs ( Figure 3C ). Inhibiting the miR-21 expression significantly reduced STC1 secretion by MSCs co-cultured with RGCs upon OGD/R ( Figure 3B , H, I) and almost completely reversed MSC-mediated anti-apoptotic effects on RGCs upon OGD/R ( Figure 3D-F) .
We next examined the expression levels of three target genes of miR-21, programmed cell death protein 4 (PDCD4), phosphatase and tensin homolog (PTEN), and Sprouty2 (SPRY2), in MSCs by real-time PCR. Inhibiting miR-21 expression increased the mRNA level of PDCD4, but not PTEN or SPRY2, in MSCs co-cultured with RGCs exposed to OGD/R ( Figure 3G ), suggesting the involvement of PDCD4 in MSC function. Western blotting further demonstrated that PDCD4 protein level was reduced in MSCs co-cultured with RGCs exposed to OGD/R, but significantly enhanced by inhibiting miR-21 expression ( Figure 3H and I) . Similarly, PDCD4 overexpression in MSCs almost completely blocked the anti-apoptotic effects on RGCs exposed to OGD/R ( Figure 3J-L) . Collectively, these findings indicate that the miR-21/PDCD4 axis plays a critical role in MSC-mediated neuroprotection of RGCs.
MSCs inhibit microglial activation for neuroprotection in acute glaucoma
Microglial activation and microglial-mediated neurotoxicity are thought to play important roles in the pathogeneses of several neurodegenerative disorders including glaucoma (Burguillos et al., 2011) . Thus, we evaluated the effects of MSCs on microglial activation in vivo and in vitro. Immunostaining was performed to detect ionized calcium-binding adaptor molecule 1 (Iba1), which is expressed and upregulated in activated microglia and thus considered as a specific marker of microglial activation (Ito et al., 2001) . In this study, the number of Iba1+ microglia was significantly increased in the retinas of eyes with acute glaucoma, and intravitreal injection of MSCs markedly reduced this elevated number ( Figure 4A and B). Both mRNA and protein levels of Iba1 were increased in ischemic retinas, which could be significantly decreased by MSC treatment, suggesting MSC-mediated inhibitory effect on microglial activation in acute glaucoma ( Figure 4C and D).
To further evaluate the anti-inflammatory effects of MSCs on microglia, BV2 cells, an established mouse microglial line, were co-cultured with MSCs for 24 h in a transwell system, followed by LPS stimulation for 6 h. LPS stimulation induced significant increase in TNF-α and IL-1β expression in BV2 cells, which was suppressed by co-culturing with MSCs ( Figure 4E and F). MSCs inhibit caspase-8-mediated microglial activation via miR-21/PDCD4 Caspase-8 has been shown to control microglial activation (Burguillos et al., 2011) . Our recent study has demonstrated that caspase-8-NLRP1/NLRP3 inflammasome signaling plays a critical role in the pathogenesis of acute glaucoma (Chi et al., 2014) . We first determined whether caspase-8 signaling is involved in MSC-mediated inhibition of microglia activation. LPS stimulation increased both caspase-8 activity and protein level of cleaved caspase-8 in BV2 cells, which was reduced by coculturing with MSCs ( Figure 5A and B). The downstream signaling molecules of caspase-8, including NLRP1, NLRP3, caspase-1, and NF-κB, were also activated in LPS-stimulated BV2 cells but suppressed by co-culturing with MSCs ( Figure 
MSC-induced neuroprotection in acute glaucoma is miR-21/PDCD4-dependent
To assess whether miR-21/PDCD4 signaling is implicated in MSC-mediated neuroprotection in acute glaucoma, mice with acute glaucoma were treated with MSCs modulated for decreased STC1 expression, decreased miR-21 expression, or PDCD4 overexpression. The neuroprotective effects of MSCs were determined by RGC survival ( Figure 6A and B) and inhibition of caspase-8-mediated microglial activation and inflammatory mediator Figure 6C-F) . Our results showed that STC1 knockdown partially, whereas miR-21 expression inhibition or PDCD4 overexpression completely blocked the neuroprotective effects by MSC treatment ( Figure 6A-F) , indicating that MSC-mediated neuroprotection in acute glaucoma is miR-21/PDCD4-dependent.
Strategies to enhance MSC-mediated neuroprotection in acute glaucoma
Finally, we attempted to augment the neuroprotective effects of MSCs in acute glaucoma. Intravitreal injection of recombinant STC1 (1-4 μg/2 μl) led to dose-dependent neuroprotection against IOP-induced RGC death, but this effect seemed not as significant as that induced by MSCs ( Figure 7A and B) . A combined injection of MSCs and STC1 did not further enhance the RGC survival compared with MSC treatment alone ( Figure 7B) . However, miR-21 overexpression or PDCD4 knockdown in MSCs augmented MSC-mediated neuroprotective effects ( Figure 7C and D). Intravitreal injection of a caspase-8 inhibitor, Z-IETD-FMK-fmk (ZIFF; 2 μM/2 μl) before IOP induction completely inhibited retinal caspase-8 activation ( Figure 7E ), but only partially protected from IOP-induced RGC death ( Figure 7F ). However, a combined injection of MSCs and the caspase-8 inhibitor augmented this effect in acute glaucoma compared with MSC injection alone ( Figure 7F ). These neuroprotective effects were further confirmed by measuring IPL thickness in H&E-stained retinal cross-sections ( Figure 7G and H) .
Discussion
In glaucoma, Johnson et al. (2010) provided the first evidence that intravitreal, but not systemic, transplantation of MSCs is neuroprotective in an ocular hypertensive glaucoma model. This finding was further supported by Hu et al. (2013) reporting that intravitreal injection of MSCs protects against RGC loss in aged rats with glaucoma. In addition, Manuguerra-Gagne et al. (2013) reported that MSCs are capable of promoting trabecular meshwork regeneration in a laser-induced glaucoma model. Their results that conditioned medium from MSCs mimic the MSC-mediated effects on trabecular meshwork regeneration suggested that secreted factors by MSCs play major roles in MSCs-mediated therapeutic effects in experimental glaucoma (Manuguerra-Gagne et al., 2013) . Furthermore, Emre et al. (2015) demonstrated that reduction of inflammatory mediators is associated with MSC-mediated protective effects in a hyaluronic acid-induced ocular hypertension glaucoma model. Collectively, these findings provide compelling evidence that MSCs are neuroprotective in glaucoma, but underlying molecular mechanisms are largely unexplored.
In this study, we examined the neuroprotective effects of MSCs and the involved molecular mechanisms in a mouse model of acute glaucoma. We found that intravitreal injection of MSCs promoted RGC survival in acute glaucoma, with significantly reduced microglial activation, decreased TNF-α, IL-1β, and ROS production, and reduced caspase-8 and caspase-3 activation. MSCs inhibited in vitro RGC apoptosis after OGD/R and microglial activation by LPS stimulation.
Previous studies have demonstrated the involvement of several neurotrophic factors in MSC-mediated neuroprotection, such as TGF-β, BDNF, STC1, PDGF-BB, NGF, and IGF-1. In the present study, only STC1 was found to play an essential role in anti-apoptotic and anti-inflammatory effects of MSCs. STC1 is a 247-amino acid protein secreted from a variety of cells as a glycosylated homodimer. It has been shown to have multiple biological effects, including cellular protection against ischemia, suppression of inflammatory responses, and reduction of apoptosis (Kz et al., 2000; Westberg et al., 2007; Huang et al., 2009; Tang et al., 2014) . In the present study, we demonstrated that neuroprotective effects by intravitreal administration of STC1 were less significant than that induced by MSCs, and the combined injection of STC1 and MSCs did not induce greater neuroprotective effects than MSCs alone. Thus, multiple factors, rather than STC1 alone, are involved in MSC-mediated neuroprotection. We found that miR-21 and its target PDCD4 are responsible for STC1 production in MSCs. In fact, the miR-21/ PDCD4 axis is responsible, at least in part, for MSC-mediated neuroprotection.
Caspase-8, a well-characterized initiator of apoptotic signaling, has been shown to have multiple apoptotic functions. Burguillos et al. (2011) have reported that caspase-8 mediates microglial activation and neuroinflammation both in vitro and in vivo. In addition, caspase-8 has been reported to promote the activation of NLRP3 inflammasome and to play critical roles in acute glaucoma (Chi et al., 2014) . In the present study, we demonstrated that both caspase-8-mediated RGC apoptosis and microglial activation are involved in the pathogenesis of IOPinduced retinal damage. Thus, inhibition of caspase-8 contributes to the enhancement of MSC-induced neuroprotection in acute glaucoma.
TNF-α, a proinflammatory cytokine, is elevated in the retinas of glaucoma patients and animal models. Mac et al. (2014) found that TNF-α exposure before optic nerve crush may be neuroprotective, while chronic TNF-α accumulation may eventually result in neuronal damage and death. Subsequently, Kyung et al. (2015) showed that reducing TNF-α expression by celastrol is associated with celastrol-mediated neuroprotection in the effects, as assayed by MTT and flow cytometry. (G) PDCD4 mRNA level was reduced in MSCs co-cultured with RGCs exposed to OGD/R, but significantly increased by dmiR-21. (H and I) STC1 protein level was increased in MSCs co-cultured with RGCs exposed to OGD/R but reversed by dmiR-21, while PDCD4 protein level was reduced upon OGD/R but significantly enhanced by dmiR-21. (J-L) PDCD4 overexpression (oPDCD4) in MSCs almost completely reversed MSC-mediated anti-apoptotic effects on RGCs upon OGD/R, as assayed by MTT and flow cytometry. NC, negative control for dmiR-21 or oPDCD4. The results are representative of three independent experiments. The data are presented as mean ± SD. **P < 0.01. same model of optic nerve crush. Importantly, Cueva et al. (2015) reported that the direct inhibition of soluble TNF-α is neuroprotective to promote RGC survival in a high IOP-induced glaucoma model. Additionally, Wang et al. (2016) reported that suppressing TNF-α production is also involved in α-aminoadipic acidinduced neuroprotection in a high IOP-induced glaucoma model. showed that intravitreal injection of MSCs robustly reduced the number of Iba1+ microglia in ischemic retinas at 24 h after reperfusion (n = 6). (C and D) Intravitreal injection of MSCs significantly reduced Iba1 expression at both mRNA and protein levels in ischemic retinas (n = 3). (E and F) BV2 microglial cells were co-cultured with MSCs at a 2:1 (microglia:MSC) ratio for 24 h in a transwell system. Co-culturing with MSCs significantly reduced the mRNA levels of TNF-α and IL-1β in BV2 cells by LPS stimulation for 6 h. (G-J) Flow cytometry showed that co-culturing with MSCs inhibited the production of TNF-α and IL-1β in LPS-stimulated BV2 cells. The data are presented as mean ± SD. **P < 0.01. These recent studies have supported the notion that TNF-α inhibition protects against retinal neuron death. In our study, MSC treatment significantly suppressed TNF-α expression in vitro and in vivo. Thus, inhibition of TNF-α expression may be involved in MSC-mediated neuroprotection in acute glaucoma.
Our study revealed a previously unrecognized MSC-mediated neuroprotective and anti-inflammatory mechanism by which the miR-21/PDCD4 axis regulates MSCs to secrete STC1 and other neuroprotective factors in a mouse model of acute glaucoma. Importantly, modulation of the miR-21/PDCD4 axis represents a promising new method to improve the neuroprotective and antiinflammatory effects of MSCs, with profound implications for the clinical application of these cells in the treatment of neurological and inflammatory diseases.
Materials and methods
Animal model of acute glaucoma
Adult male C57BL/6 mice were purchased from the Guangzhou Animal Testing Center. The animal care and use strictly conformed to the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. This study was approved by the Committee of Animal Care of the Zhongshan Ophthalmic Center.
The murine acute glaucoma model was generated as previously reported (Chi et al., 2014) . Briefly, the mice were anesthetized by intraperitoneal injection of a mixture of 100 mg/kg ketamine and 10 mg/kg xylazine. The corneas were topically anesthetized with 0.5% tetracaine hydrochloride, and the pupils were dilated with 1% tropicamide. The anterior chamber of the Figure 6 MSC-induced neuroprotection in acute glaucoma is miR-21/PDCD4-dependent. (A and B) FG labeling showed that STC1 knockdown (dSTC1) in MSCs partially, whereas miR-21 expression inhibition (dmiR-21) and PDCD4 overexpression (oPDCD4) almost completely reversed MSC-mediated neuroprotection on RGC survival on Day 7 after reperfusion. (C-F) dSTC1 in MSCs partially, whereas dmiR-21 and oPDCD4 almost completely reversed the inhibition of caspase-8-mediated microglial activation and inflammatory mediator production in retinas at 24 h after reperfusion. NC, negative control for dSTC1, dmiR-21, or oPDCD4. The data are presented as mean ± SD. *P < 0.05, **P < 0.01. right eye of each mouse was cannulated using a 30-gauge infusion needle connected to a normal saline reservoir to maintain an IOP of 110 mmHg for 1 h. The animal model was evaluated by monitoring IOP and retinal ischemia. IOP was measured by tenonometer (Tono-Pen XL; Medtronic Solan) to verify that IOP was maintained at 110 mmHg. Complete retinal ischemia, which is evidenced by a whitening of the anterior segment of the eye and blanching of the retinal arteries, was confirmed by microscopic examination. A sham procedure was performed without elevating the pressure in the contralateral left eye to serve as the control. After 1 h, the needle was withdrawn, and IOP was normalized.
Intravitreal injections
MSCs (5 × 10 4 /2 μl), recombinant STC1 (1, 2, 4 μg/2 μl, PROSPEC), the caspase-8 inhibitor Z-IETD-fmk (20 μM/2 μl; Calbiochem), or 2 μl of the control vehicle was injected into the vitreous cavity of eyes before acute elevation of IOP.
Histological examination
On Day 7 after reperfusion, the eyes were collected and fixed in formalin and embedded in paraffin. Three 5-μm-thick sections through the optic disk of each eye were prepared in a standard manner and stained with H&E. Retinal IPL thickness was measured in four adjacent areas of the inferior retina within 1 mm of the optic nerve using Axiovision software (Carl Zeiss), and the mean value was calculated.
RGC labeling and quantification
The mice were anesthetized with a mixture of 100 mg/kg ketamine and 10 mg/kg xylazine by intraperitoneal injection and were then placed in a stereotactic apparatus (Kopf Instruments). FG (4% (w/v) diluted in saline, 1 μl per injection; Invitrogen) was injected into both superior colliculi. To ensure proper RGC labeling, we waited for 7 days to allow the retrograde transport of FG before the animals were sacrificed. On Day 3 after reperfusion, FG-positive RGCs were identified with a fluorescence microscope (AxioImager; Carl Zeiss) after retinal flat mount preparation. Survived RGCs (gold dots) were counted using Image Pro Plus (Version 6.0; Media Cybernetics).
Cell culture
Bone marrow-derived MSCs were isolated from C57BL/6 mice as previously described (Akiyama et al., 2012) . Briefly, bone marrow cells were flushed from the bone cavities of the femurs and tibias with α-MEM containing 2% heat-inactivated fetal bovine serum (FBS). Single-suspension murine bone marrowderived nucleated cells were seeded at a density of 15 × 10 6 cells in 100-mm culture dishes (Corning Costar, Corning) and maintained at 37°C and 5% CO 2 . Nonadherent cells were removed after 48 h, and adherent cells were maintained for 16 days in α-MEM supplemented with 20% FBS, 2 mM L-glutamine, 55 μM 2-mercaptoethanol, 100 U/ml penicillin, and 100 μg/ml streptomycin. Colonies formed by adherent cells were passaged once for additional experimental use. Flow cytometric analyses demonstrated that the MSCs expressed high levels of CD29, CD44, and CD90 but did not express the hematopoietic marker CD34, CD45, or CD11b (eBioscience) (data not shown).
Primary RGCs were obtained from C57BL/6 mice according to a two-step immunopanning protocol as described previously (Sivakumar et al., 2011) . In brief, retinas were dissociated from 6-8-day-old mice to produce single-cell suspension. The retinal suspension was incubated in OX-42-coated flasks to promote glial cell adherence. Nonadherent cells were placed in Thy-1-coated flasks. Finally, adherent cells were collected and incubated at 37°C and 5% CO 2 in serum-free Neurobasal Medium (Invitrogen) containing glutamine, B27 supplement, BDNF, CTNF, gentamicin, and forskolin. The cells were incubated with neutralizing antibodies specific for mouse TGF-β1, BDNF, STC1, PDGF-BB, NGF, IGF-1, VEGF, and TNF-α and isotype-matched antibodies (10 μg/ml; Abcam). Primary RGCs obtained from C57BL/6 mice were verified as real RGCs according to cell morphology and Brn3a expression level (Supplementary Figure S1) .
The BV2 microglial cell line (Shanghai Cell Bank of Academia Sinica) was cultured in high-glucose (4.5 g/ml) DMEM (Gibco) supplemented with 10% FBS and 1% penicillin/streptomycin at 37°C and 5% CO 2 in a humidified incubator.
RGC viability and apoptosis assays and flow cytometry
For OGD/R, cells were washed twice with phosphate-buffered saline (PBS), and the culture medium was replaced with glucosefree DMEM. Then, the cells were placed in a modular incubator chamber (Billups-Rothenberg, Inc.) filled with a gas mixture of 5% CO 2 and 95% N 2 at 37°C for 3 h. Control cells were incubated in serum-free medium with 4.5 g/L D-glucose under normoxic condition (5% CO 2 /95% air) for the same duration. At the end of the exposure period, the cells were reoxygenated under normoxic condition, with the addition of a glucose solution, for 24 h. Cell viability and proliferation were measured using a VybrantH MTT Cell Proliferation Assay Kit (Invitrogen) according to the manufacturer's protocol. In addition, RGC apoptosis was assessed by flow cytometry using a propidium iodide (PI)-PE and Annexin V-FITC detection kit according to the manufacturer's instructions (Keygen Biotech).
Staining for cell surface marker CD11b (eBioscience) and intracellular cytokines TNF-α and IL-1β (eBioscience) was performed according to standard protocols. Flow cytometric analysis using FACS (BD Biosciences) was performed following standard protocols.
miRNA array
Total RNA was quantified using a NanoDrop ND-2000 (Thermo Scientific), and RNA integrity was assessed using an Agilent Bioanalyzer 2100 (Agilent Technologies). Sample labeling, microarray hybridization, and washing were performed according to the manufacturer's standard protocols. Briefly, the total RNA was dephosphorylated, denatured, and then labeled with Cyanine-3-CTP. Then, the labeled RNA was purified and hybridized onto the array. Next, the microarray was washed and scanned with an Agilent Scanner G2505C (Agilent Technologies). Feature Extraction software (version 10.7.1.1, Agilent Technologies) was used to analyze the array images to obtain raw data. Genespring software (version 13.1, Agilent Technologies) was employed to complete basic analysis of the raw data. The raw data were normalized using the quantile algorithm. The probes that fluoresced in 100% of the samples under 1 of the 2 conditions were flagged as 'Detected' and selected for further data analysis. The threshold for the upregulation and downregulation of gene expression was a fold change >2.0 and a P-value <0.05.
Cell transfection
STC1 siRNA, PDCD4 siRNA, their respective negative controls, and transfection reagents were purchased from Santa Cruz Biotechnology. The transfection of MSCs with siRNA was performed according to the manufacturer's instructions. The miR-21 analog and inhibitor and their respective negative controls were purchased from RiboBio. Transfection of MSCs with the miR-21 analog (50 nM) and inhibitor (50 nM) was performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. In addition, transfection of MSCs with the plasmid pEGFP-C1 or pEGFP-C1-PDCD4 (constructed by SIDANSAI) was carried out using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocols.
Statistical analyses
Statistical analyses were performed with appropriate one-way ANOVA followed by Bonferroni post hoc tests using SPSS software (Version 16.0; SPSS, Chicago, Ill). A P-value <0.05 was considered significant.
Further information on immunofluorescence and evaluation of microglial activation, western blotting, ELISA, and real-time PCR can be found in Supplementary Materials and methods.
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